FTLFNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
FITLIFE BRANDS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$8.23−0.16 (-1.91%)
Close on Oct 19, 2026
- Market cap
- $81.53M
- P/E (TTM)
- 43.3
- Dividend yield
- –
FITLIFE BRANDS, INC. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Irwin [Member] | $14.14M | $12.85M | $12.64M | $6.82M | – | $0 | $0 | – | – | – | – | 53.2% | – |
| Legacy FitLife [Member] | $12.41M | $12.48M | $21.59M | $12.86M | $7.30M | $22.24M | $13.51M | $6.80M | $6.96M | $6.14M | $6.70M | 46.8% | +70.0% |
| MRC [Member] | – | – | – | – | $6.27M | $6.87M | $7.21M | $7.46M | $7.49M | $6.90M | $7.20M | – | – |
| Muscle Pharm [Member] | – | – | – | $3.81M | $2.56M | $2.82M | $2.47M | $2.67M | $2.10M | – | – | – | – |
By product or service
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $25.09M | $24.14M | $24.23M | $22.36M | $15.48M | $14.18M | $15.23M | $16.26M | $15.84M | – | – | 94.5% | +62.1% |
| Non-US [Member] | $1.46M | $1.19M | $1.68M | $1.13M | $643.00K | $835.00K | $747.00K | $668.00K | $705.00K | – | – | 5.5% | +126.6% |
From the segment and revenue-disaggregation notes of Fitlife Brands's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.